US OptionsDetailed Quotes
AKLI240719C1000
- 0.05
- 0.000.00%
15min DelayClose Jul 2 09:30 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume183 Open Interest1.00Strike Price0.00Turnover0.00%IV--PremiumJul 19, 2024Expiry Date--Intrinsic Value100Multiplier15DDays to Expiry--Extrinsic Value100Contract Size--Options Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Akili Stock Discussion
$Akili(AKLI.US)$
Delivered through an engaging video game experience, EndeavorOTC is indicated to improve attention function as measured by computer-based testing in men and women with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. EndeavorOTC is Akili's second digita...
Akili Announces FDA Authorization of Endeavorotc, the First FDA Clearance of a Digital Treatment for Adults With Adhd Through a Video Game
Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game
Akili (Nasdaq: AKLI) has received FDA clearance for EndeavorOTC®, a digital therapeutic game designed for adults with ADHD. This approval marks the first over-the-counter digital treatment for ADHD, improving attention function as verified through clinical trials. EndeavorOTC, available on iOS and Android, effectively enhances attention m...
No comment yet